Founded in 2016 by Sabrina Mogle and Christopher Novashinski, RareMoon was born from both personal experience and professional purpose.
Sabrina, having lost her father to a rare disease and later two more family members to the same condition, was driven by a strong desire to change the future for patients like her loved ones. Chris, whose own life was also deeply affected by that same rare disease, shared her sense of urgency. When they discovered not only a shared personal connection to rare disease but also complementary professional paths, the vision for RareMoon became clear.
Chris and Sabrina set out with a clear mission: to do whatever it takes to help advance life-changing therapies to the patients who need them most. From the beginning, along with their long-time partner and friend, Fred Loussala, they were committed to building more than a consulting firm; they wanted to create a place where people could thrive, be proud of what they do, and love how they do it.
Today, RareMoon is known not only for its strategic and operational regulatory expertise, but for a team and a culture built on quality, accountability, and integrity. The RareMoon name carries a reputation for consulting responsibly and delivering with care, because for the team behind it, this work is personal.
"Working alongside the RareMoon team is one of the most rewarding parts of my role. Every person here brings deep expertise, heart, and an unwavering commitment to helping our clients succeed. It's an honor to build something meaningful with such a dedicated group."~Chris Novashinski, RareMoon's COO
We apply an "eyes-on/hands-on" approach with ownership and accountability, staying fully engaged in the success of every project.
We are driven by the opportunity to bring novel therapies to patients with rare diseases and unmet medical needs.
We consult responsibly and provide honest and direct advice, delivering solutions that align with the best interests of our clients and the patients they aim to serve.
We strive to understand your passion, objectives, and commitments. By asking the right questions and collaborating closely, we build partnerships that foster success for all stakeholders.
"I am very impressed with RareMoon's high-quality and innovative approaches to regulatory strategies and their commitment to drug development for rare and orphan diseases. Thank you very much for the excellent results through our collaborations; it has been a great pleasure to work with the team."
"RMC has been our reliable, trusted partner, providing thoughtful strategic input and advice through various stages of the drug development process. Our collaboration has spanned preclinical and clinical stages and has contributed to our success."